MA42376B1 - Dérivés d'oxopyridine substitués - Google Patents
Dérivés d'oxopyridine substituésInfo
- Publication number
- MA42376B1 MA42376B1 MA42376A MA42376A MA42376B1 MA 42376 B1 MA42376 B1 MA 42376B1 MA 42376 A MA42376 A MA 42376A MA 42376 A MA42376 A MA 42376A MA 42376 B1 MA42376 B1 MA 42376B1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- substituted oxopyridine
- oxopyridine derivatives
- substituted
- cardiovascular disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne des dérivés de dérivés d'oxopyridine substitués et leurs procédés de préparation, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de troubles cardio-vasculaires, de préférence de troubles thrombotiques ou thromboemboliques, d'oedèmes, et de troubles ophtalmiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176099 | 2015-07-09 | ||
| EP16157350 | 2016-02-25 | ||
| PCT/EP2016/065787 WO2017005725A1 (fr) | 2015-07-09 | 2016-07-05 | Dérivés d'oxopyridine substitués |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42376A MA42376A (fr) | 2018-05-16 |
| MA42376B1 true MA42376B1 (fr) | 2021-04-30 |
Family
ID=56345141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42376A MA42376B1 (fr) | 2015-07-09 | 2016-07-05 | Dérivés d'oxopyridine substitués |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US10421742B2 (fr) |
| EP (1) | EP3319956B1 (fr) |
| JP (1) | JP6871180B2 (fr) |
| KR (1) | KR102596164B1 (fr) |
| CN (2) | CN108026072B (fr) |
| AU (1) | AU2016289746B2 (fr) |
| CA (1) | CA2990901A1 (fr) |
| CL (1) | CL2018000039A1 (fr) |
| CO (1) | CO2018000113A2 (fr) |
| CR (1) | CR20180017A (fr) |
| CU (1) | CU24512B1 (fr) |
| CY (1) | CY1123996T1 (fr) |
| DK (1) | DK3319956T3 (fr) |
| DO (1) | DOP2018000004A (fr) |
| EA (1) | EA036208B1 (fr) |
| EC (1) | ECSP18001308A (fr) |
| ES (1) | ES2856554T3 (fr) |
| GE (1) | GEP20197046B (fr) |
| HK (1) | HK1255045A1 (fr) |
| HR (1) | HRP20210459T1 (fr) |
| HU (1) | HUE053552T2 (fr) |
| IL (1) | IL256556B (fr) |
| JO (1) | JO3703B1 (fr) |
| LT (1) | LT3319956T (fr) |
| MA (1) | MA42376B1 (fr) |
| MX (1) | MX2018000076A (fr) |
| MY (1) | MY196640A (fr) |
| NI (1) | NI201800001A (fr) |
| PE (1) | PE20180538A1 (fr) |
| PH (1) | PH12018500057A1 (fr) |
| PL (1) | PL3319956T3 (fr) |
| RS (1) | RS61584B1 (fr) |
| SI (1) | SI3319956T1 (fr) |
| SV (1) | SV2018005610A (fr) |
| TN (1) | TN2018000011A1 (fr) |
| TW (1) | TWI717367B (fr) |
| UA (1) | UA122341C2 (fr) |
| UY (1) | UY36780A (fr) |
| WO (1) | WO2017005725A1 (fr) |
| ZA (1) | ZA201800826B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10077265B2 (en) * | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016146606A1 (fr) * | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose |
| UA125520C2 (uk) | 2016-08-31 | 2022-04-13 | Джянгсу Хенгруй Медісін Ко., Лтд. | Похідні оксопіколінаміду, спосіб їх отримання та їх фармацевтичне застосування |
| SG11202006710RA (en) | 2018-03-15 | 2020-08-28 | Bayer Ag | Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives |
| MX2020010635A (es) | 2018-04-10 | 2020-10-28 | Bayer Pharma AG | Un derivado de oxopiridina sustituido. |
| CN112004810B (zh) | 2018-07-02 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
| AR115870A1 (es) | 2018-07-31 | 2021-03-10 | Sumitomo Chemical Co | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ |
| JP2022513919A (ja) * | 2018-12-17 | 2022-02-09 | バイエル・アクチエンゲゼルシヤフト | 血栓性または血小板塞栓性疾患および／または血栓性または血小板塞栓性合併症の治療および／または予防のための置換オキソピリジン誘導体 |
| EP3898634A1 (fr) | 2018-12-21 | 2021-10-27 | Bayer Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| CA3124220A1 (fr) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Derives d'oxopyridine substitues |
| KR20220084301A (ko) * | 2019-09-27 | 2022-06-21 | 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 | FXIa 억제제와 이의 제조 방법 및 의약 용도 |
| US20230373972A1 (en) | 2020-09-17 | 2023-11-23 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Piperazine derivative, preparation method therefor and use thereof |
| CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
| WO2022189278A1 (fr) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Formes posologiques pharmaceutiques comprenant du (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluorométhyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzénaheptaphane-74-carboxamide |
| WO2022189280A1 (fr) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| MX2023010614A (es) | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas cristalinas de (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?, 5-dioxo-14-(trifluoro-metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2, 3]triazola-2(1,2),7(1)-dibencenaheptafano-74-carboxamida. |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| CN113666826B (zh) * | 2021-07-30 | 2024-03-26 | 五邑大学 | 一种芳基或杂芳基甲氧基化反应的方法 |
| WO2023174399A1 (fr) * | 2022-03-18 | 2023-09-21 | 苏州晶云药物科技股份有限公司 | Forme cristalline d'un dérivé d'oxopyridine substitué et son procédé de préparation |
| CN116535392B (zh) * | 2023-06-26 | 2023-09-05 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物的制备方法及中间体和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| WO2002042273A2 (fr) | 2000-11-07 | 2002-05-30 | Bristol-Myers Squibb Company | Derives d'acide utiles comme inhibiteurs de serines proteases |
| EP1526131A1 (fr) | 2003-10-22 | 2005-04-27 | Graffinity Pharmaceuticals Aktiengesellschaft | Aminoalkyl-pyrazinones et -pyridones et leur utilisation comme inhibiteurs de la thrombine |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| JP5227311B2 (ja) | 2006-05-05 | 2013-07-03 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤 |
| EP2091947A2 (fr) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Activateurs de glucokinase |
| US9079929B2 (en) | 2011-10-14 | 2015-07-14 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| AU2012356374B2 (en) | 2011-12-21 | 2017-06-22 | Ono Pharmaceutical Co., Ltd. | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| SG11201500271UA (en) * | 2012-08-03 | 2015-03-30 | Bristol Myers Squibb Co | Dihydropyridone p1 as factor xia inhibitors |
| EP2968207A4 (fr) | 2013-03-14 | 2016-09-28 | Chdi Foundation Inc | Inhibiteurs d'histone désacétylase, et compositions et méthodes d'utilisation de ceux-ci |
| WO2014160592A2 (fr) * | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | Inhibiteurs du facteur xia |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| CA2918814C (fr) | 2013-07-23 | 2021-10-12 | Bayer Pharma Aktiengesellschaft | Derives de l'oxopyridine substitues et utilisation desdits derives comme facteur xia/plasma |
| WO2015063093A1 (fr) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substituée |
| TWI688564B (zh) | 2014-01-31 | 2020-03-21 | 美商必治妥美雅史谷比公司 | 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物 |
| EP3138839B1 (fr) * | 2014-02-14 | 2020-10-28 | Sichuan Haisco Pharmaceutical Co., Ltd. | Dérivé de pyrimidone ou de pyridone, procédé de préparation associé et application correspondante |
| EP3197872B1 (fr) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | (2h)-2-oxopyridines en tant qu'inhibiteurs du facteur xia pour le traitement de maladies thrombotiques |
| US10077265B2 (en) | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| WO2016046164A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| EP3197880B1 (fr) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués à effet anti-inflammatoire et anti-thrombotique |
| EP3197889B1 (fr) | 2014-09-24 | 2018-08-01 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
| US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| EP3331872B1 (fr) * | 2015-08-05 | 2019-09-25 | Bristol-Myers Squibb Company | Nouveaux inhibiteurs de fxia dérivés de glycine substitués |
-
2016
- 2016-07-03 JO JOP/2016/0136A patent/JO3703B1/ar active
- 2016-07-05 CU CU2018000001A patent/CU24512B1/es unknown
- 2016-07-05 UA UAA201801270A patent/UA122341C2/uk unknown
- 2016-07-05 GE GEAP201614692A patent/GEP20197046B/en unknown
- 2016-07-05 DK DK16734672.5T patent/DK3319956T3/da active
- 2016-07-05 EA EA201890111A patent/EA036208B1/ru not_active IP Right Cessation
- 2016-07-05 EP EP16734672.5A patent/EP3319956B1/fr active Active
- 2016-07-05 SI SI201631060T patent/SI3319956T1/sl unknown
- 2016-07-05 JP JP2017568177A patent/JP6871180B2/ja active Active
- 2016-07-05 HU HUE16734672A patent/HUE053552T2/hu unknown
- 2016-07-05 CA CA2990901A patent/CA2990901A1/fr active Pending
- 2016-07-05 MX MX2018000076A patent/MX2018000076A/es unknown
- 2016-07-05 ES ES16734672T patent/ES2856554T3/es active Active
- 2016-07-05 KR KR1020187003576A patent/KR102596164B1/ko active IP Right Grant
- 2016-07-05 RS RS20210338A patent/RS61584B1/sr unknown
- 2016-07-05 US US15/742,063 patent/US10421742B2/en active Active
- 2016-07-05 MA MA42376A patent/MA42376B1/fr unknown
- 2016-07-05 PE PE2018000035A patent/PE20180538A1/es unknown
- 2016-07-05 MY MYPI2018700053A patent/MY196640A/en unknown
- 2016-07-05 WO PCT/EP2016/065787 patent/WO2017005725A1/fr active Application Filing
- 2016-07-05 LT LTEP16734672.5T patent/LT3319956T/lt unknown
- 2016-07-05 PL PL16734672T patent/PL3319956T3/pl unknown
- 2016-07-05 AU AU2016289746A patent/AU2016289746B2/en active Active
- 2016-07-05 CN CN201680052335.5A patent/CN108026072B/zh active Active
- 2016-07-05 CR CR20180017A patent/CR20180017A/es unknown
- 2016-07-05 TN TNP/2018/000011A patent/TN2018000011A1/en unknown
- 2016-07-05 CN CN202110557164.4A patent/CN113292539B/zh active Active
- 2016-07-07 TW TW105121492A patent/TWI717367B/zh active
- 2016-07-08 UY UY0001036780A patent/UY36780A/es active IP Right Grant
-
2017
- 2017-12-25 IL IL256556A patent/IL256556B/en active IP Right Grant
-
2018
- 2018-01-04 NI NI201800001A patent/NI201800001A/es unknown
- 2018-01-05 DO DO2018000004A patent/DOP2018000004A/es unknown
- 2018-01-05 CL CL2018000039A patent/CL2018000039A1/es unknown
- 2018-01-05 PH PH12018500057A patent/PH12018500057A1/en unknown
- 2018-01-08 SV SV2018005610A patent/SV2018005610A/es unknown
- 2018-01-08 EC ECIEPI20181308A patent/ECSP18001308A/es unknown
- 2018-01-09 CO CONC2018/0000113A patent/CO2018000113A2/es unknown
- 2018-02-08 ZA ZA2018/00826A patent/ZA201800826B/en unknown
- 2018-11-07 HK HK18114169.6A patent/HK1255045A1/zh unknown
-
2019
- 2019-08-08 US US16/535,120 patent/US11180471B2/en active Active
-
2021
- 2021-03-18 HR HRP20210459TT patent/HRP20210459T1/hr unknown
- 2021-03-26 CY CY20211100269T patent/CY1123996T1/el unknown
- 2021-10-18 US US17/504,243 patent/US20230024752A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42376B1 (fr) | Dérivés d'oxopyridine substitués | |
| MA35844B1 (fr) | Pyrimidines et triazines annelées substituées et leur utilisation | |
| MA41060B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA55434A (fr) | Compositions comprenant des souches bactériennes | |
| MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
| MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
| MA41010B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
| MA34019B1 (fr) | Aryltriazolone liée à un bis-aryle et son utilisation | |
| MA40755B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA40754B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA38925B1 (fr) | Dérivés de phénylalanine substitués | |
| MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA38365A1 (fr) | Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante | |
| MA33123B1 (fr) | 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA41977B1 (fr) | Imidazopyrazinones utilisées comme inhibiteurs de pde1 | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
| MA46235B1 (fr) | 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation | |
| MA37700B1 (fr) | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments | |
| MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
| MA37928A1 (fr) | Tri(hétéro)arylpyrazoles et leur utilisation | |
| MA41059A (fr) | Compositions comprenant des souches bactériennes |